Supporting Information
|
|
- Myra Glenn
- 5 years ago
- Views:
Transcription
1 Supporting Information Horwitz et al. 73/pnas A Copies ml - C 3NC Days Gp2 residue G458D G459D T278A 7/36 N28 K D A28T ID# 697 ID# 698 ID# 7 ID# 7 ID# 73 ID# 76 ID# D human IgG ( g/ml).5mg 3NC7 i.v. n= T /2 = 2. Fig. S. Treatment of HIV- infected humanized mice (hu-mice) with 3NC7 transiently reduces viral load and rapidly selects for antibody resistance mutations. (A) Viral loads from seven mice treated with the antibody 3NC7 (.5 mg twice per week s.c.). Antibody treatment began at day. Each line represents a single mouse. ( and C) Gp2 sequences were cloned from each mouse after 5 d of treatment with 3NC7 (C). Red and green dots indicate nonsynonymous and synonymous mutations, respectively, relative to HIV- YU2. Resistance mutations were identified in the CD4 binding site (CD4bs) at residues YU2 (28 282) and YU2 ( ). The representation of each mutation among the viral sequences obtained in C is shown in, where the numbers in the center reflect the number of mice (7) and the total number of gp2 sequences obtained (36). (D) The serum half-life of 3NC7 in NOD/Rag / /IL-2Rγ null (NRG) mice was 2. d. Three NRG mice were injected with.5 mg 3NC7 i.v. at day and followed for 9 d. 3NC7 concentration was measured by human IgG-specific ELISA and the half-life was calculated using GraphPad Prism 5.. A C Copies ml Log change Average Copies ml *** Wk Wk 6 Fig. S2. Combination immunotherapy with 3NC7, PG6, and -74 is sufficient to suppress viremia in HIV- YU2 infected hu-mice. (A) Plasma viral loads for hu-mice treated with combination immunotherapy were monitored weekly using the highly sensitive Abbot HIV-RealTime Assay. Each line represents a single animal. Treatment began at day. Antibodies were administered s.c. at. mg per antibody, twice per week, for a total of 6 wk. () Fold change in viral load (shown in A) from the baseline measurement for each animal. Red line shows the geometric mean viral load change at each time point. (C) Combination immunotherapy resulted in a highly significant drop in viral load in all animals (n = 5) after 6 wk of continuous treatment (***P <., Wilcoxon signed rank test, two-tailed). The average viral load drop was 2.5 log HIV- RNA copies per milliliter. Horwitz et al. of7
2 Copies ( cells) - Intracellular HIV- DNA n.s. PMC Spleen P.LN Copies ( cells) - Intracellular HIV- RNA 7 n.s. PMC Spleen P.LN Fig. S3. Cell-associated HIV- DNA and RNA levels in immunotherapy-treated mice (Fig. ) are similar among lymphoid tissue compartments. (A and ) Cellassociated HIV- DNA (A) and RNA () levels per million human lymphoid cells isolated from the indicated tissue compartment (P.LN, peripheral lymph nodes). Each line represents a single mouse. Gray bars reflect geometric averages for each tissue compartment. n.s., not statistically significant. A Copies ml - Untreated 7 ART (3 wks) 7 ART Untreated Days ID# ID# 26 ID# 222 ID# 336 ID# 224 ID# 27 ART ID# 326 ID# 329 ID# 335 Gp2 residue ID# 344 ID# 64 Fig. S4. Treatment of HIV- YU2 infected hu-mice with antiretroviral therapy (ART) rapidly lowers viral load, but viremia returns to pretreatment levels after stopping ART. (A) Untreated mice exhibit sustained viremia for over 2 d after infection (green line, geometric average). Three weeks of treatment with ART [tenofovir disproxil-fumarate/emtricitabine/raltegravir (TDF/FTC/RAL), daily by oral gavage] reduces viral load by an average of 2. log RNA copies per milliliter plasma. Twelve to 23 d after stopping ART, viral load returns to pretreatment levels. () gp2 sequences obtained from untreated mice (Upper) and ART-treated mice after stopping ART. Red and green dots indicate nonsynonymous and synonymous mutations, respectively, relative to HIV- YU2. ART-treated mice did not carry recurring mutations in gp2 that differed from those identified in untreated mice. Horwitz et al. 2of7
3 ART G54W G54W ART G54W 4RAL 7 ART Ab 7 ART Ab RAL Copies ml Fig. S5. Mice treated with ART plus G54W combination therapy exhibit rapid viral rebound after both treatments are stopped. (A and ) Mice were treated with ART (TDF/FTC/RAL) for a total of 3 wk. Five into ART, combination therapy was initiated with G54W. Combination therapy was terminated after 3 wk on ART and mice were placed on either G54W (A, copied from Fig. 3) or raltegravir () only. (For clarity, only mice below the limit of viral load detection at the time combination therapy was stopped are shown.) Each line represents a single mouse. In contrast to mice continuing on G54W monotherapy, viremia in mice continuing on raltegravir monotherapy quickly rebounded to pretreatment levels, indicating that antibody monotherapy sustained viremic suppression after combination therapy was stopped. Amino acid changes during bnab therapy PG G54W ID# 686 ID# 67 ID# 667 ID# 664 ID# 396 ID# 348 ID# 342 ID# 582 3NC7 ID# 58 ID# 578 ID# 566 Fig. S6. Viruses in mice that escaped antibody therapy (Figs. 3 and 5A) harbor amino acid changes in gp2 in regions that are targeted by the antibodies (). Amino acid changes in mice treated with either G54W or 3NC7 carried mutations at either (or both) YU2 (279 28) or YU2 ( ). The one mouse escaping -74 had the mutation YU2 N332K, and mice escaping PG6 had mutations at YU2 6/62.. Klein F, et al. (22) HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 492(7427):8 22. Horwitz et al. 3of7
4 Escape during therapy AAV Passive Mouse IC 5 bnab ID# W ID# 348 >5 4546W ID# 396 >5-74 ID# 664 >5 PG6 ID# 566 >5 3NC7 ID# 582 >5 3NC7 ID# 683 >5-74 ID# NC7 ID# 52 >5 3NC7 Post-therapy rebound ID# W ID# W ID# W ID# W ID# Fig. S7. Viruses emerging during antibody therapy are resistant to antibody neutralization, whereas viruses emerging after therapy remain sensitive to neutralization. Pseudoviruses expressing envelope from representative viral clones isolated from hu-mice during and after antibody therapy were assayed for neutralization in a TZM-bl assay (antibody IC 5 s in micrograms per milliliter are shown). In all cases, viruses cloned from mice during antibody therapy were highly resistant to the respective antibody used in treatment (escape during therapy). This was true also for mice with reemergent virus during adenoassociated virus (AAV)-directed antibody therapy. y comparison, viruses cloned from mice after antibody therapy, when antibody concentrations in serum were low, remained highly sensitive to the respective antibodies used in therapy (posttherapy rebound). This suggests that reemergent virus after antibody therapy was a product of latently infected cells. Horwitz et al. 4of7
5 mino acid changes after bnab therapy PG6 ID# ID# 399 ID# 333 ID# G54W ID# 33 ID# 7 ID# 3NC7 ID# 585 ID# 572 Fig. S8. Gp2 sequences from virus that rebounded after antibody concentrations in plasma decreased to subtherapeutic levels (Figs. 4 and 5) generally did not harbor mutations at sites known to confer antibody resistance. Only one of nine mice for which sequences could be obtained carried mutations at resistance sites, signifying that the antibodies sustained viral suppression until rebound virus emerged from latently infected cells after antibody concentrations decayed. One -74 treated mouse, ID number 399, had viral clones bearing mutations in the -74 binding site at either YU2 D3G or YU2 N332T. Of note, viremia in this mouse rebounded while antibody was still present (34 μg/ml) and this mutant virus was likely resistant to -74 at this concentration. Horwitz et al. 5of7
6 Plasma higg (ug/ml) C Copies ml - D Gp2 residue E 5 7 AAV expression (2d) AAV alone AAV+ART Copies ml ID# 498 ID# 5 ID# 52 ID# 55 ID# 59 Gp2 residue ART AAV Escape Virus ART+AAV 3NC Days Escape Virus µg ml - ID# 5 ID# 52 ID# 55 ID# 59 Fig. S9. Mice treated with ART and AAV-directed expression of 3NC7 antibody exhibit sustained viral suppression after ART cessation. (A) Mice were injected i.v. with 2 genomic copies of AAV 3NC7 in the presence or absence of ART. Mice treated with ART (TDF/FTC/RAL) had significantly lower antibody expression 2 d after AAV injection (P =.4, Mann Whitney test), possibly owing to inhibition of AAV transduction by nucleotide analogs. () The five ART plus AAV 3NC7 -treated mice with detectable antibody levels at 2 d after AAV injection (bracketed in A) were treated for a total of 28 d with ART. Each line represents a single mouse. ART was terminated and viral loads were monitored for an additional 8 d. Although two mice quickly escaped AAV 3NC7 therapy upon ART termination, the remaining three mice were aviremic for more than 8 d after ART was withdrawn. The proportion of mice that remained controlled by AAV 3NC7 was similar to results obtained for passive 3NC7 therapy (Fig. 3). The two surviving mice at day 8 were reinfected with virus from mice that escaped 3NC7 therapy and carried resistance mutations to that antibody. Upon reinfection virus reemerged in both mice, signifying that prolonged viral suppression was due to AAV 3NC7 and not to loss of the human graft. (C) Individual viral load plots for each mouse shown in, with yellow lines/symbols showing gp2-binding human IgG for each mouse. (D and E) Gp2 sequences obtained from (D) the two mice that escaped AAV 3NC7 after stopping ART carried mutations conferring resistance to 3NC7 and (E) virus that reemerged in AAV 3NC7 -controlled mice after reinfection at day 8 carried mutations conferring 3NC7 resistance that were present in the reinfection inoculum. Red and green dots indicate nonsynonymous and synonymous mutations, respectively, relative to HIV- YU2. Horwitz et al. 6of7
7 bnabs Primary T CD4+ target cells (FarRed+) + + Infected primary T CD4+ donor cells No infection Preincubation 2 of coculture G54W 3NC7 % of Gag+ target cells No Antibody -74 PG6 Gag C Inhibition (%) 5 FarRed G54W 3NC7-74 PG [Ab] µg/ml. 5. IC 5 (ug/ml) HIV- YU-2 Cellassociated Cell-free 45-46W NC PG6 7 X* Cell-free Cell-associated D * <.2 µg/ml.2-.5 µg/ml µg/ml ~5% inhibition at 5 µg/ml Fig. S. Antibodies G54W, 3NC7, and -74 block cell contact-mediated viral transmission in vitro. (A) Experimental design of an assay to measure antibody blockage of viral transmission under cell contact-permitting (cell-associated) conditions. Primary HIV- infected CD4+ T cells were preincubated for h with broadly neutralizing antibodies (bnabs) before coculture with autologous target cells stained with FarRed dye. After 48 h of coculture, the fraction of productively infected (Gag+) target cells was measured by flow cytometry (example shown in ). () Flow cytometric analysis of Gag+/FarRed+ cells after coincubation with HIV- YU2 infected donor cells (or uninfected donor cells, No infection). Donor cells were preincubated with the indicated bnab at 5 μg/ml (or no antibody) before coincubation with FarRed+ target cells. Plots show Gag+/FarRed+ cells after 48 h of coincubation with donor cells. (C) Antibodymediated inhibition of cell-free (dashed lines) and cell-associated (solid lines) viral transmission for the indicated bnab. Cell-free infections were performed on HeLa-derived P4C5 target cells and quantitated by measuring β-gal after 36 h. Results are mean ± SD from three to five independent experiments. Curves represent fitted results. (D) Summary of IC 5 values for cell-free and cell-associated viral transmission from C. Whereas all four antibodies potently inhibited cellfree virus transmission, G54W, 3NC7, and -74 also potently inhibited viral transmission under cell contact-permitting conditions. PG6 reached only a partial IC 5 for cell-associated viral transmission at the maximum concentration tested (5 μg/ml), possibly accounting for its reduced efficacy in vivo relative to the other bnabs tested. Horwitz et al. 7of7
Supporting Information
Supporting Information Walker et al. 1.173/pnas.111753118 - JR-CSF 1 3 1 4 1 5 1 6 1 7 1 8 blank beads protein A beads JR-FL - 1 3 1 4 1 5 1 6 1 7 1 8 - MGRM-C26 1 3 1 4 1 5 1 6 1 7 1 8 reciprocal serum
More informationSupplementary Figure 1. ALVAC-protein vaccines and macaque immunization. (A) Maximum likelihood
Supplementary Figure 1. ALVAC-protein vaccines and macaque immunization. (A) Maximum likelihood tree illustrating CRF01_AE gp120 protein sequence relationships between 107 Envs sampled in the RV144 trial
More informationSupplementary information. Early development of broad neutralizing antibodies in HIV-1 infected infants
Supplementary information Early development of broad neutralizing antibodies in HIV-1 infected infants Leslie Goo, Vrasha Chohan, Ruth Nduati, Julie Overbaugh Supplementary Figure 1. Neutralization profile
More informationDynamics of HIV-1 Infection and Therapy In Vivo
Rockefeller University Digital Commons @ RU Student Theses and Dissertations 0 Dynamics of HIV- Infection and Therapy In Vivo Joshua Abraham Horwitz Follow this and additional works at: http://digitalcommons.rockefeller.edu/
More informationModule R: Recording the HIV Reservoir
Module R: Recording the HIV Reservoir Satish K. Pillai, Ph.D. MODULE LEADER Satish Pillai amfar Institute for HIV Cure Research Module R Team Michael Busch Timothy Henrich Sheila Keating Sulggi Lee Henry
More informationSpleen. mlns. E Spleen 4.1. mlns. Spleen. mlns. Mock 17. Mock CD8 HIV-1 CD38 HLA-DR. Ki67. Spleen. Spleen. mlns. Cheng et al. Fig.
C D E F Mock 17 Mock 4.1 CD38 57 CD8 23.7 HLA-DR Ki67 G H I Cheng et al. Fig.S1 Supplementary Figure 1. persistent infection leads to human T cell depletion and hyper-immune activation. Humanized mice
More informationIdentification of Mutation(s) in. Associated with Neutralization Resistance. Miah Blomquist
Identification of Mutation(s) in the HIV 1 gp41 Subunit Associated with Neutralization Resistance Miah Blomquist What is HIV 1? HIV-1 is an epidemic that affects over 34 million people worldwide. HIV-1
More informationIgG3 regulates tissue-like memory B cells in HIV-infected individuals
SUPPLEMENTARY INFORMATION Articles https://doi.org/10.1038/s41590-018-0180-5 In the format provided by the authors and unedited. IgG3 regulates tissue-like memory B cells in HIV-infected individuals Lela
More informationHIV cure: current status and implications for the future
HIV cure: current status and implications for the future Carolyn Williamson, PhD Head of Medical Virology, Faculty Health Sciences, University of Cape Town CAPRISA Research Associate, Centre of Excellence
More informationResistance Post Week 48 in ART-Experienced, Integrase Inhibitor-Naïve Subjects with Dolutegravir (DTG) vs. Raltegravir (RAL) in SAILING (ING111762)
Resistance Post Week 48 in ART-Experienced, Integrase Inhibitor-Naïve Subjects with Dolutegravir (DTG) vs. Raltegravir (RAL) in SAILING (ING111762) MR Underwood 1, F DeAnda 1, D Dorey 2, K Hightower 1,
More informationTherapeutic Immunization with Autologous DC Pulsed with Autologous Inactivated HIV-1 Infected Apoptotic Cells
Therapeutic Immunization with Autologous DC Pulsed with Autologous Inactivated HIV-1 Infected Apoptotic Cells Sharon A. Riddler, MD, MPH University of Pittsburgh May 2008 Slide 1 HIV and DC Vaccines During
More informationProfessor Jonathan Weber
HIV/AIDS at 30: Back to the Future BHIVA / Wellcome Trust Multidisciplinary Event to mark World AIDS Day 2011 British HIV Association (BHIVA) 2011 HIV/AIDS at 30: Back to the Future BHIVA / Wellcome Trust
More informationSupplementary Materials for
www.sciencetranslationalmedicine.org/cgi/content/full//49/eaao4/dc Supplementary Materials for TLR agonists induce transient viremia and reduce the viral reservoir in SIV-infected rhesus macaques on antiretroviral
More informationSupplementary Materials for
www.sciencetranslationalmedicine.org/cgi/content/full/8/352/352ra110/dc1 Supplementary Materials for Spatially selective depletion of tumor-associated regulatory T cells with near-infrared photoimmunotherapy
More informationAntiretroviral Prophylaxis and HIV Drug Resistance. John Mellors University of Pittsburgh
Antiretroviral Prophylaxis and HIV Drug Resistance John Mellors University of Pittsburgh MTN Annual 2008 Outline Two minutes on terminology Origins of HIV drug resistance Lessons learned from ART Do these
More informationSupporting Information Table of Contents
Supporting Information Table of Contents Supporting Information Figure 1 Page 2 Supporting Information Figure 2 Page 4 Supporting Information Figure 3 Page 5 Supporting Information Figure 4 Page 6 Supporting
More informationNature Medicine: doi: /nm.4322
1 2 3 4 5 6 7 8 9 10 11 Supplementary Figure 1. Predicted RNA structure of 3 UTR and sequence alignment of deleted nucleotides. (a) Predicted RNA secondary structure of ZIKV 3 UTR. The stem-loop structure
More informationBlocking antibodies and peptides. Rat anti-mouse PD-1 (29F.1A12, rat IgG2a, k), PD-
Supplementary Methods Blocking antibodies and peptides. Rat anti-mouse PD-1 (29F.1A12, rat IgG2a, k), PD- L1 (10F.9G2, rat IgG2b, k), and PD-L2 (3.2, mouse IgG1) have been described (24). Anti-CTLA-4 (clone
More informationSUPPLEMENTARY INFORMATION
doi:1.138/nature1554 a TNF-α + in CD4 + cells [%] 1 GF SPF 6 b IL-1 + in CD4 + cells [%] 5 4 3 2 1 Supplementary Figure 1. Effect of microbiota on cytokine profiles of T cells in GALT. Frequencies of TNF-α
More informationSupplementary Figure 1.
Supplementary Figure 1. Female Pro-ins2 -/- mice at 5-6 weeks of age were either inoculated i.p. with a single dose of CVB4 (1x10 5 PFU/mouse) or PBS and treated with αgalcer or control vehicle. On day
More informationNature Medicine: doi: /nm.2109
HIV 1 Infects Multipotent Progenitor Cells Causing Cell Death and Establishing Latent Cellular Reservoirs Christoph C. Carter, Adewunmi Onafuwa Nuga, Lucy A. M c Namara, James Riddell IV, Dale Bixby, Michael
More informationSupplemental Table 1. Clinical and epidemiological characteristics of the
Tendeiro et al. Supplemental Digital Content 1_ Page 2 of 1 Supplemental Table 1. Clinical and epidemiological characteristics of the therapy naïve and treated infected individuals. a Number [male/female]
More informationPRO140 SC Monotherapy (MT) Provides Long-Term, Full Virologic Suppression in HIV Patients
PRO140 SC Monotherapy (MT) Provides Long-Term, Full Virologic Suppression in HIV Patients Jay Lalezari, Kush Dhody, Ula Kowalczyk, Kazem Kazempour, Nader Pourhassan, and Paul J. Maddon 1 ASM Microbe 2016
More informationEstablishment and Targeting of the Viral Reservoir in Rhesus Monkeys
Establishment and Targeting of the Viral Reservoir in Rhesus Monkeys Dan H. Barouch, M.D., Ph.D. Center for Virology and Vaccine Research Beth Israel Deaconess Medical Center Ragon Institute of MGH, MIT,
More informationHIV replication and selection of resistance: basic principles
HIV replication and selection of resistance: basic principles 26th International HIV Drug Resistance and Treatment Strategies Workshop Douglas Richman 6 November 2017 CLINICAL DATA DURING SIXTEEN WEEKS
More informationSummary Report for HIV Random Clinical Trial Conducted in
Summary Report for HIV Random Clinical Trial Conducted in 9-2014 H.T. Banks and Shuhua Hu Center for Research in Scientific Computation North Carolina State University Raleigh, NC 27695-8212 USA Eric Rosenberg
More informationpplementary Figur Supplementary Figure 1. a.
pplementary Figur Supplementary Figure 1. a. Quantification by RT-qPCR of YFV-17D and YFV-17D pol- (+) RNA in the supernatant of cultured Huh7.5 cells following viral RNA electroporation of respective
More informationB220 CD4 CD8. Figure 1. Confocal Image of Sensitized HLN. Representative image of a sensitized HLN
B220 CD4 CD8 Natarajan et al., unpublished data Figure 1. Confocal Image of Sensitized HLN. Representative image of a sensitized HLN showing B cell follicles and T cell areas. 20 µm thick. Image of magnification
More informationSupplementary Information. Supplementary Figure 1
Supplementary Information Supplementary Figure 1 1 Supplementary Figure 1. Functional assay of the hcas9-2a-mcherry construct (a) Gene correction of a mutant EGFP reporter cell line mediated by hcas9 or
More informationLynn Morris. "Plan B"- bnabs for HIV prevention
"Plan B"- bnabs for HIV prevention Lynn Morris National Institute for Communicable Diseases, a division of the National Health Laboratory Service (NHLS) of South Africa, University of the Witwatersrand,
More informationT-Pharmacytes for the Targeted Eradication of HIV Reservoirs
T-Pharmacytes for the Targeted Eradication of HIV Reservoirs Walker Lab Rachel O Connor Alicja Trocha Dan Karel Irvine Lab Stefanie Mueller Humanized Mouse Core Vlad Vrbanac Andy Tager Todd Allen Darrell
More informationDEBATE ON HIV ENVELOPE AS A T CELL IMMUNOGEN HAS BEEN GAG-GED
DEBATE ON HIV ENVELOPE AS A T CELL IMMUNOGEN HAS BEEN GAG-GED Viv Peut Kent Laboratory, University of Melbourne, Australia WHY ENVELOPE? Env subject to both humoral and cellular immune responses Perhaps
More informationSupplementary Figure 1. Characterization of basophils after reconstitution of SCID mice
Supplementary figure legends Supplementary Figure 1. Characterization of after reconstitution of SCID mice with CD4 + CD62L + T cells. (A-C) SCID mice (n = 6 / group) were reconstituted with 2 x 1 6 CD4
More informationACTIVITY OF BRINCIDOFOVIR (BCV) AGAINST MURINE POLYOMAVIRUS (MUPYV) IN A MOUSE INFECTION MODEL
ACTIVITY OF BRINCIDOFOVIR (BCV) AGAINST MURINE POLYOMAVIRUS (MUPYV) IN A MOUSE INFECTION MODEL Kidney Week 2018 Poster # SA-PO642 BRINCIDOFOVIR(BCV) DEMONSTRATES ANTIVIRAL ACTIVITY AGAINST MURINE POLYOMAVIRUS
More informationApproaching a Cure Daniel R. Kuritzkes, MD
Approaching a Cure Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker is a consultant and/or has received speaking honoraria
More informationLong-acting Antivirals Where Are We Headed? Are We Ready? Carl W. Dieffenbach, Ph.D. Director Division of AIDS, NIAID May 3, 2018
Long-acting Antivirals Where Are We Headed? Are We Ready? Carl W. Dieffenbach, Ph.D. Director Division of AIDS, NIAID May 3, 2018 Global HIV Statistics 2017 People living with HIV in 2016 New HIV infections
More informationAlternate Antibody-Based Therapeutic Strategies To Purge the HIV Cell Reservoir
Alternate Antibody-Based Therapeutic Strategies To Purge the HIV Cell Reservoir Giuseppe Pantaleo, M.D. Professor of Medicine Head, Division of Immunology and Allergy Executive Director, Swiss Vaccine
More informationSupporting Information
Supporting Information Sui et al..7/pnas.997 Pre-CLP CM9 LA9 SL Tat# Pol Vif % Tetramer + CD + CD + Vac+IL- +IL- Vac Fig. S. Frequencies of six different CD + CD + Mamu-A*-tetramer + cells were measured
More informationVan Rompay et al. Retrovirology 2012, 9:57
Van Rompay et al. Retrovirology 2012, 9:57 RESEARCH Open Access Prolonged tenofovir treatment of macaques infected with K65R reverse transcriptase mutants of SIV results in the development of antiviral
More informationDestruction of the Residual Active HIV-1 Reservoir by Env-specific Immunotoxin
Destruction of the Residual Active HIV-1 Reservoir by Env-specific Immunotoxin J. Victor Garcia-Martinez, Ph.D. University of North Carolina, at Chapel Hill IAS 2013 Towards an HIV Cure Symposium Delivering
More informationSupplementary Figure 1. Generation of knockin mice expressing L-selectinN138G. (a) Schematics of the Sellg allele (top), the targeting vector, the
Supplementary Figure 1. Generation of knockin mice expressing L-selectinN138G. (a) Schematics of the Sellg allele (top), the targeting vector, the targeted allele in ES cells, and the mutant allele in
More informationPredicting the Impact of a Nonsterilizing Vaccine against Human Immunodeficiency Virus
JOURNAL OF VIROLOGY, Oct. 2004, p. 11340 11351 Vol. 78, No. 20 0022-538X/04/$08.00 0 DOI: 10.1128/JVI.78.20.11340 11351.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved. Predicting
More informationcure research HIV & AIDS
Glossary of terms HIV & AIDS cure research Antiretroviral Therapy (ART) ART involves the use of several (usually a cocktail of three or more) antiretroviral drugs to halt HIV replication. ART drugs may
More informationJournal of Microbes and Infection,June 2007,Vol 2,No. 2. (HBsAg)2 , (PCR) 1762/ 1764
68 2007 6 2 2 Journal of Microbes and Infection,June 2007,Vol 2,No. 2 2 S 1 1 1 2 2 3 1 (HBsAg)2 ( YIC) S 5 30g 60g YIC ( HBV) DNA > 2 log10 e (HBeAg), 6 DNA, 1 YIC 1, (PCR) (0 ) (44 ) HBV DNA S 2, S a
More informationBroadly Neutralizing Antibodies for HIV Eradication
DOI 10.1007/s11904-016-0299-7 HIV PATHOGENESIS AND TREATMENT (AL LANDAY, SECTION EDITOR) Broadly Neutralizing Antibodies for HIV Eradication Kathryn E. Stephenson 1,2 & Dan H. Barouch 1,2 # The Author(s)
More informationSupplementary Figure 1. Deletion of Smad3 prevents B16F10 melanoma invasion and metastasis in a mouse s.c. tumor model.
A B16F1 s.c. Lung LN Distant lymph nodes Colon B B16F1 s.c. Supplementary Figure 1. Deletion of Smad3 prevents B16F1 melanoma invasion and metastasis in a mouse s.c. tumor model. Highly invasive growth
More informationSUPPLEMENTARY FIG. S1. MVC inhibition curves in NP2-CD4/CCR5 cells. Luciferase reporter viruses pseudotyped with baseline (black solid lines) and MVC
Supplementary Data SUPPLEMENTARY FIG. S1. MVC inhibition curves in NP2-CD4/CCR5 cells. Luciferase reporter viruses pseudotyped with baseline (black solid lines) and MVC failure Envs (black dotted lines)
More informationSupplementary Figures
Supplementary Figures Supplementary Figure 1. NKT ligand-loaded tumour antigen-presenting B cell- and monocyte-based vaccine induces NKT, NK and CD8 T cell responses. (A) The cytokine profiles of liver
More informationProfessor Anna Maria Geretti
THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014 Professor Anna Maria Geretti Institute of Infection & Global Health, University of Liverpool 1-4 April 2014, Arena and Convention Centre Liverpool THIRD JOINT
More informationResistance Characteristics of Integrase Inhibitors
Resistance Characteristics of Integrase Inhibitors Madrid, November 2016 Jonathan M Schapiro, MD National Hemophilia Center, Israel Stanford University School of Medicine, USA Disclaimer Presentation includes
More informationMID 36. Cell. HIV Life Cycle. HIV Diagnosis and Pathogenesis. HIV-1 Virion HIV Entry. Life Cycle of HIV HIV Entry. Scott M. Hammer, M.D.
Life Cycle Diagnosis and Pathogenesis Scott M. Hammer, M.D. -1 Virion Entry Life Cycle of Entry -1 virion -1 Virus virion envelope Cell membrane receptor RELEASE OF PROGENY VIRUS REVERSE Co- TRANSCRIPTION
More informationSUPPORTING INFORMATIONS
SUPPORTING INFORMATIONS Mice MT/ret RetCD3ε KO α-cd25 treated MT/ret Age 1 month 3 mnths 6 months 1 month 3 months 6 months 1 month 3 months 6 months 2/87 Survival 87/87 incidence of 17/87 1 ary tumor
More informationIn vivo analysis of HIV replication and persistence in the myeloid compartment
In vivo analysis of HIV replication and persistence in the myeloid compartment J. Honeycutt, A. Wahl, J. Foster, R.A. Spagnulo and J. Victor Garcia Division of Infections Diseases UNC Center for AIDS Research
More informationCD4 T Cell Decline Is Not Associated With Amino Acid Changes in HIV-1 gp120
CD4 T Cell Decline Is Not Associated With Amino Acid Changes in HIV-1 gp120 Colin Wikholm and Isai Lopez BIOL 368: Bioinformatics Laboratory Department of Biology Loyola Marymount University November 15,
More informationSupporting Online Material for
www.sciencemag.org/cgi/content/full/1175194/dc1 Supporting Online Material for A Vital Role for Interleukin-21 in the Control of a Chronic Viral Infection John S. Yi, Ming Du, Allan J. Zajac* *To whom
More information0.1 Immunology - HIV/AIDS. 0.2 History & biology of HIV
0.1 mmunology - HV/ADS n our previous models we assumed a homogeneous population where everyone was susceptible and infectious to the same degree. n contrast, the dynamics of STDs is affected by the general
More informationTo test the possible source of the HBV infection outside the study family, we searched the Genbank
Supplementary Discussion The source of hepatitis B virus infection To test the possible source of the HBV infection outside the study family, we searched the Genbank and HBV Database (http://hbvdb.ibcp.fr),
More informationClinical Development of ABX464, drug candidate for HIV Functional Cure. Chief Medical Officer ABIVAX
Clinical Development of ABX464, drug candidate for HIV Functional Cure Jean-Marc Steens, MD Chief Medical Officer ABIVAX 1 DECLARATION OF CONFLICT OF INTEREST GSK ABIVAX 2 ABX464: Mechanism of Action ABX464
More informationCrystallization-grade After D After V3 cocktail. Time (s) Time (s) Time (s) Time (s) Time (s) Time (s)
Ligand Type Name 6 Crystallization-grade After 447-52D After V3 cocktail Receptor CD4 Resonance Units 5 1 5 1 5 1 Broadly neutralizing antibodies 2G12 VRC26.9 Resonance Units Resonance Units 3 1 15 1 5
More informationSupporting Information
Supporting Information Desnues et al. 10.1073/pnas.1314121111 SI Materials and Methods Mice. Toll-like receptor (TLR)8 / and TLR9 / mice were generated as described previously (1, 2). TLR9 / mice were
More informationNK cell flow cytometric assay In vivo DC viability and migration assay
NK cell flow cytometric assay 6 NK cells were purified, by negative selection with the NK Cell Isolation Kit (Miltenyi iotec), from spleen and lymph nodes of 6 RAG1KO mice, injected the day before with
More informationAntibody Dependent Cellular Cytotxic activity: Past and Future. Guido Ferrari, M.D. Duke University Medical Center
Antibody Dependent Cellular Cytotxic activity: Past and Future Guido Ferrari, M.D. Duke University Medical Center Mechanism of Antibody Dependent Cellular Cytotoxicity (ADCC) ADCC Effector Cells (NK, monocytes/macrophages,
More informationHuman Immunodeficiency Virus Type-1 Myeloid Derived Suppressor Cells Inhibit Cytomegalovirus Inflammation through Interleukin-27 and B7-H4
Human Immunodeficiency Virus Type-1 Myeloid Derived Suppressor Cells Inhibit Cytomegalovirus Inflammation through Interleukin-27 and B7-H4 Ankita Garg, Rodney Trout and Stephen A. Spector,,* Department
More informationPearson r = P (one-tailed) = n = 9
8F4-Specific Lysis, % 1 UPN1 UPN3 8 UPN7 6 Pearson r =.69 UPN2 UPN5 P (one-tailed) =.192 4 UPN8 n = 9 2 UPN9 UPN4 UPN6 5 1 15 2 25 8 8F4, % Max MFI Supplementary Figure S1. AML samples UPN1-UPN9 show variable
More informationVirologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection
HIV Virologic effects of broadly neutralizing antibody VRC1 administration during chronic HIV-1 infection Rebecca M. Lynch, 1 * Eli Boritz, 1 * Emily E. Coates, 1 Adam DeZure, 1 Patrick Madden, 1 Pamela
More informationSupplementary Figure 1
Supplementary Figure 1 Supplementary Figure 1 SNARE Probes for FRET/2pFLIM Analysis Used in the Present Study. mturquoise (mtq) and Venus (Ven) are in blue and yellow, respectively. The soluble N-ethylmaleimide-sensitive
More informationSupplementary Figure 1. Efficiency of Mll4 deletion and its effect on T cell populations in the periphery. Nature Immunology: doi: /ni.
Supplementary Figure 1 Efficiency of Mll4 deletion and its effect on T cell populations in the periphery. Expression of Mll4 floxed alleles (16-19) in naive CD4 + T cells isolated from lymph nodes and
More informationViral Reservoirs and anti-latency interventions in nonhuman primate models of SIV/SHIV infection
Viral Reservoirs and anti-latency interventions in nonhuman primate models of SIV/SHIV infection Koen Van Rompay California National Primate Research Center University of California Davis Outline Introduction
More informationA VACCINE FOR HIV BIOE 301 LECTURE 10 MITALI BANERJEE HAART
BIOE 301 LECTURE 10 MITALI BANERJEE A VACCINE FOR HIV HIV HAART Visit wikipedia.org and learn the mechanism of action of the five classes of antiretroviral drugs. (1) Reverse transcriptase inhibitors (RTIs)
More informationImmunodeficiency. (2 of 2)
Immunodeficiency (2 of 2) Acquired (secondary) immunodeficiencies More common Many causes such as therapy, cancer, sarcoidosis, malnutrition, infection & renal disease The most common of which is therapy-related
More informationNature Neuroscience: doi: /nn Supplementary Figure 1
Supplementary Figure 1 EGFR inhibition activates signaling pathways (a-b) EGFR inhibition activates signaling pathways (a) U251EGFR cells were treated with erlotinib (1µM) for the indicated times followed
More informationSupplementary Figure 1. Enhanced detection of CTLA-4 on the surface of HIV-specific
SUPPLEMENTARY FIGURE LEGEND Supplementary Figure 1. Enhanced detection of CTLA-4 on the surface of HIV-specific CD4 + T cells correlates with intracellular CTLA-4 levels. (a) Comparative CTLA-4 levels
More informationTitle: Neutralization resistance of HIV-1 virological synapse-mediated infection is. Running Title: Virological-synapse neutralization resistance
JVI Accepts, published online ahead of print on 2 May 2012 J. Virol. doi:10.1128/jvi.00230-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 Title: Neutralization resistance
More informationCROI 2016 Review: Immunology and Vaccines
Frontier AIDS Education and Training Center CROI 2016 Review: Immunology and Vaccines Meena Ramchandani MD MPH Acting Instructor, University of Washington March 2016 This presentation is intended for educational
More informationNK mediated Antibody Dependent Cellular Cytotoxicity in HIV infections
NK mediated Antibody Dependent Cellular Cytotoxicity in HIV infections Amy Chung Dr. Ivan Stratov Prof. Stephen Kent ADCC process consists of Target cell QuickTime and a TIFF (Uncompressed) FcγR decompressor
More informationImmunity and Infection. Chapter 17
Immunity and Infection Chapter 17 The Chain of Infection Transmitted through a chain of infection (six links) Pathogen: Disease causing microorganism Reservoir: Natural environment of the pathogen Portal
More informationGeneration of Neutralizing Antibodies and Divergence of SIVmac239 in Cynomolgus Macaques Following Short- Term Early Antiretroviral Therapy
Generation of Neutralizing Antibodies and Divergence of SIVmac239 in Cynomolgus Macaques Following Short- Term Early Antiretroviral Therapy Gülşen Özkaya Şahin 1., Emma J. Bowles 2., Joe Parker 2, Hannes
More informationIntroduction to HIV Drug Resistance. Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School
Introduction to HIV Drug Resistance Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School Objectives 1. Describe the epidemiology of HIV drug resistance in sub-saharan Africa. 2.
More informationSupplemental Figure 1
Supplemental Figure 1 1a 1c PD-1 MFI fold change 6 5 4 3 2 1 IL-1α IL-2 IL-4 IL-6 IL-1 IL-12 IL-13 IL-15 IL-17 IL-18 IL-21 IL-23 IFN-α Mut Human PD-1 promoter SBE-D 5 -GTCTG- -1.2kb SBE-P -CAGAC- -1.kb
More informationIdentification and Characterization of CD4 T cells actively transcribing HIV RNA in Peripheral Blood
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Identification and Characterization of CD4 T cells actively transcribing
More informationChronic HIV-1 Infection Frequently Fails to Protect against Superinfection
Chronic HIV-1 Infection Frequently Fails to Protect against Superinfection Anne Piantadosi 1,2[, Bhavna Chohan 1,2[, Vrasha Chohan 3, R. Scott McClelland 3,4,5, Julie Overbaugh 1,2* 1 Division of Human
More informationJournal of Infectious Diseases Advance Access published July 11, Effect of Antiretroviral Therapy on HIV Reservoirs in Elite Controllers
Journal of Infectious Diseases Advance Access published July 11, 2013 1 Effect of Antiretroviral Therapy on HIV Reservoirs in Elite Controllers Tae-Wook Chun 1,6, J. Shawn Justement 1, Danielle Murray
More informationHow HIV Causes Disease Prof. Bruce D. Walker
How HIV Causes Disease Howard Hughes Medical Institute Massachusetts General Hospital Harvard Medical School 1 The global AIDS crisis 60 million infections 20 million deaths 2 3 The screen versions of
More informationSupplementary Figures
Supplementary Figures Supplementary Fig. 1. Galectin-3 is present within tumors. (A) mrna expression levels of Lgals3 (galectin-3) and Lgals8 (galectin-8) in the four classes of cell lines as determined
More informationARV Mode of Action. Mode of Action. Mode of Action NRTI. Immunopaedia.org.za
ARV Mode of Action Mode of Action Mode of Action - NRTI Mode of Action - NNRTI Mode of Action - Protease Inhibitors Mode of Action - Integrase inhibitor Mode of Action - Entry Inhibitors Mode of Action
More informationCD4 + T cells recovered in Rag2 / recipient ( 10 5 ) Heart Lung Pancreas
a CD4 + T cells recovered in Rag2 / recipient ( 1 5 ) Heart Lung Pancreas.5 1 2 4 6 2 4 6 Ctla4 +/+ Ctla4 / Ctla4 / Lung Ctla4 / Pancreas b Heart Lung Pancreas Ctla4 +/+ Ctla4 / Ctla4 / Lung Ctla4 / Pancreas
More informationSupplementary Figure 1. SC35M polymerase activity in the presence of Bat or SC35M NP encoded from the phw2000 rescue plasmid.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 Supplementary Figure 1. SC35M polymerase activity in the presence of Bat or SC35M NP encoded from the phw2000 rescue plasmid. HEK293T
More informationSUPPLEMENTARY INFORMATION
doi:10.1038/nature10134 Supplementary Figure 1. Anti-inflammatory activity of sfc. a, Autoantibody immune complexes crosslink activating Fc receptors, promoting activation of macrophages, and WWW.NATURE.COM/NATURE
More informationTable S1. Viral load and CD4 count of HIV-infected patient population
Table S1. Viral load and CD4 count of HIV-infected patient population Subject ID Viral load (No. of copies per ml of plasma) CD4 count (No. of cells/µl of blood) 28 7, 14 29 7, 23 21 361,99 94 217 7, 11
More informationHIV 101: Fundamentals of HIV Infection
HIV 101: Fundamentals of HIV Infection David H. Spach, MD Professor of Medicine University of Washington Seattle, Washington Learning Objectives After attending this presentation, learners will be able
More informationAnti-HIV Activity of Modified Milk Proteins and Fragments Thereof Dr. René Floris, NIZO Food Research, The Netherlands
Anti-HIV Activity of Modified Milk Proteins and Fragments Thereof Dr. René Floris, NIZ Food Research, The Netherlands René Floris has studied chemistry at Leiden University and obtained his PhD degree
More informationSupplementary Figures
Supplementary Figures Supplementary Fig. 1. Surface thiol groups and reduction of activated T cells. (a) Activated CD8 + T-cells have high expression levels of free thiol groups on cell surface proteins.
More information227 28, 2010 MIDTERM EXAMINATION KEY
Epidemiology 227 April 28, 2010 MIDTERM EXAMINATION KEY Select the best answer for the multiple choice questions. There are 64 questions and 9 pages on the examination. Each question will count one point.
More informationReceived 17 May 2008/Returned for modification 1 July 2008/Accepted 25 July 2008
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Oct. 2008, p. 3617 3632 Vol. 52, No. 10 0066-4804/08/$08.00 0 doi:10.1128/aac.00654-08 Copyright 2008, American Society for Microbiology. All Rights Reserved. Antiviral
More informationHepatitis B Case Studies
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Hepatitis B Case Studies Nina Kim, MD MSc Associate Professor of Medicine University of Washington Harborview Madison Clinic and Hepatitis & Liver Clinic No
More informationsequences of a styx mutant reveals a T to A transversion in the donor splice site of intron 5
sfigure 1 Styx mutant mice recapitulate the phenotype of SHIP -/- mice. (A) Analysis of the genomic sequences of a styx mutant reveals a T to A transversion in the donor splice site of intron 5 (GTAAC
More informationOverview of role of immunologic markers in HIV diagnosis
Overview of role of immunologic markers in HIV diagnosis Savita Pahwa, M.D. Departments of Microbiology & Immunology and Pediatrics University of Miami, Miller School of Medicine, Miami, Florida Background:
More informationSupplemental Materials for. Effects of sphingosine-1-phosphate receptor 1 phosphorylation in response to. FTY720 during neuroinflammation
Supplemental Materials for Effects of sphingosine-1-phosphate receptor 1 phosphorylation in response to FTY7 during neuroinflammation This file includes: Supplemental Table 1. EAE clinical parameters of
More informationRecent Insights into HIV Pathogenesis and Treatment: Towards a Cure
Recent Insights into HIV Pathogenesis and Treatment: Towards a Cure Deborah Persaud, M.D. Associate Professor Department of Pediatrics Division of Infectious Diseases Johns Hopkins University School of
More informationBIT 120. Copy of Cancer/HIV Lecture
BIT 120 Copy of Cancer/HIV Lecture Cancer DEFINITION Any abnormal growth of cells that has malignant potential i.e.. Leukemia Uncontrolled mitosis in WBC Genetic disease caused by an accumulation of mutations
More information